The USPTO published a patent application (US20260092112A1) claiming methods and compositions using anti-CTLA-4 antibodies to treat adenoid cystic carcinoma. The application includes CPC classifications C07K 16/2818, A61K 9/0019, A61K 38/00, and A61P 35/04, indicating claims related to immunotherapeutic antibodies and pharmaceutical compositions for cancer treatment.

Pharmaceutical companies and researchers developing immunooncology therapeutics for head and neck cancers should review this application for potential freedom-to-operate concerns. Drug manufacturers pursuing similar CTLA-4 targeting approaches for adenoid cystic carcinoma may need to consider licensing discussions or design-around strategies. No immediate compliance actions are required as patent applications are informational publications rather than regulatory requirements.